Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial
Conclusions
Placebo is not non-inferior to colchicine in prevention of gout flares in the first 6 months of starting allopurinol using the ‘start-low go-slow’ strategy. After stopping colchicine, gout flares rise with no difference in the mean number of gout flares/month between groups over a 12-month period.
Trial registration number
ACTRN 12618001179224.
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Stamp, L., Horne, A., Mihov, B., Drake, J., Haslett, J., Chapman, P. T., Frampton, C., Dalbeth, N. Tags: ARD Lay summaries, ARD, Crystal arthropathies Source Type: research